Phase 3 Start
NVO: Phase3_Start: Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
October 26, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 26, 2026
- Company
- Novo Nordisk A/S (NVO)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Start
Phase3_Start: Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
- Company
- Novo Nordisk A/S (NVO)